Mental health experts have welcomed TGA approval of Servier's LATUDA (lurasidone HCl) for the treatment of schizophrenia in adolescents (aged 13-17 years) as “an important therapy” for young patients with what is a debilitating mental illness. …
Latest Video
New Stories
-
What next for payment reform?
February 20, 2019 - - Latest News -
New report calls for greater focus on secondary CV events
February 20, 2019 - - Latest News -
Fee 'crunch' for smaller companies and patient populations
February 20, 2019 - - Latest News -
Partnership to manage Biomedical Translation Bridge Program
February 20, 2019 - - Latest News -
Gilead's Rob Hetherington: 'Workplaces have come such a long way'
February 19, 2019 - - Latest News -
Department of Health reveals facts on key listing stage
February 19, 2019 - - Latest News -
Response reveals impact of higher price cut threshold
February 19, 2019 - - Latest News